Relmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer Study

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Relmada Therapeutics, Inc. is one of them.

Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotechnology company developing therapies for central nervous system disorders and oncology. Its leading candidates include NDV-01, a controlled-release formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC), and sepranolone, a neurosteroid in development for conditions such as Prader-Willi Syndrome and Tourette Syndrome.

In August 2025, the company reported strong second-quarter results and six-month follow-up data from its Phase 2 NDV-01 study, showing a 91% overall response rate with a favorable safety profile. Enrollment is ongoing, with nine- and twelve-month updates expected, and a Phase 3 registration trial planned for the first half of 2026. In parallel, Relmada Therapeutics, Inc. (NASDAQ:RLMD) is preparing a Phase 2 trial of sepranolone in Prader-Willi Syndrome within the same timeframe.

The near-term pipeline is anchored by NDV-01’s potential as a transformative bladder cancer therapy, while advancing sepranolone reflects the business’s commitment to tackling severe metabolic and neurological disorders with limited treatment options. For investors monitoring emerging trends alongside the best psychedelic stocks, RLMD’s dual-focus strategy highlights the growing appeal of companies pursuing innovative, high-impact therapies.

By pursuing a dual-focus strategy in oncology and neurosteroid therapy, Relmada Therapeutics, Inc. (NASDAQ:RLMD) positions itself at the forefront of biopharma innovation. The positive NDV-01 results and upcoming sepranolone trials highlight accelerating clinical progress, a diversified pipeline, and the potential to deliver breakthrough treatments across high-need therapeutic areas.

While we acknowledge the potential of RLMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.